Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Pasithea Therapeutics Corp ( (KTTA) ) is now available.
On May 4, 2026, Pasithea Therapeutics announced it had appointed Kartik Krishnan, M.D., Ph.D., as chief medical officer, effective May 1, 2026, tasking him with leading clinical development and medical strategy as PAS-004 progresses in trials for NF1-associated plexiform and cutaneous neurofibromas. The move brings a veteran of Genentech’s cobimetinib program and multiple oncology-focused biotechs into Pasithea’s executive team, and is paired with a refreshed equity incentive program that grants sizable stock option awards to executives, employees and non-employee directors to better align compensation with peers and recent capital-raising activity.
In connection with Krishnan’s hire, Pasithea signed an executive employment agreement providing a $500,000 base salary, bonus eligibility and a significant stock option grant vesting over three years, reinforcing his long-term stake in the PAS-004 program. The broader option awards, set at Nasdaq market prices as of May 1, 2026, vest over one year for directors and three years for management and staff, and are designed to retain key talent and recalibrate ownership incentives as the company advances its clinical pipeline in competitive MEK-inhibitor and rare-disease markets.
The most recent analyst rating on (KTTA) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Pasithea Therapeutics Corp stock, see the KTTA Stock Forecast page.
More about Pasithea Therapeutics Corp
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing its lead drug candidate PAS-004, a next-generation macrocyclic MEK inhibitor targeting RASopathies, MAPK pathway-driven tumors and other diseases. The company is currently running Phase 1 trials of PAS-004 in patients with advanced cancers and in neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas.
Average Trading Volume: 411,373
Technical Sentiment Signal: Sell
Current Market Cap: $20.97M
Find detailed analytics on KTTA stock on TipRanks’ Stock Analysis page.